RESULTS	Additionally , there was earlier pruritus improvement ( median , day 3 vs day 6 ; p = 0.034 ) in the pimecrolimus group , as well as a reduced need for CS by 37 % ( p = 0.020 ) [ corrected ] Adverse events ( AEs ) incidence and type were comparable between groups .\